Table 2.
Multivariable Cox model for overall survival immunotherapy alone subset
| n=393 | P value of variable | HR (95% CI) | P value of contrasts |
| BMI | 0.202 | 1.02 (0.99 to 1.05) | – |
| Gender | 0.922 | ||
| Female | Reference | ||
| Male | 1.01 (0.77 to 1.33) | 0.922 | |
| BRAF mutation | 0.034* | ||
| Negative | Reference | ||
| Positive | 0.56 (0.32 to 0.96) | 0.034* | |
| Disease stage | 0.114 | ||
| M1a+M1b | Reference | ||
| M1c+M1d | 1.25 (0.95 to 1.66) | 0.114 | |
| LDH value | <0.001* | ||
| 0 | Reference | ||
| ≥1 | 1.71 (1.28 to 2.28) | <0.001* | |
| ECOG PS value | <0.001* | ||
| 0 | Reference | ||
| ≥1 | 2.11 (1.47 to 3.03) | <0.001* | |
| Age | 0.700 | 1.00 (0.99 to 1.01) | – |
| Type of first-line ICIs | 0.514 | ||
| Anti-PD1 | Reference | ||
| Ipilimumab | 1.14 (0.77 to 1.69) | 0.514 |
*For LDH, the PH assumption is not satisfied.
BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; LDH, lactate dehydrogenase; PH, proportional hazard.